Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
12/18/2014 > 204 patent applications in 157 patent subcategories.

20140371131 - Adhesive biopolymers and uses thereof: and methods of preparing the polymers, wherein A is a dihydroxyphenyl moiety; A′-A″ is a pair of crosslinked dihydroxyphenyl moieties; B, B′ and B″ are each a biopolymer; and L, L′ and L″ are each a linking moiety. Further provided are crosslinked adhesives prepared from the polymers, methods of generating... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20140371132 - Codon signature for neuromyelitis optica: The present invention provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject utilizing a unique a codon signature in B cells that has now been associated with NMO and not with any other autoimmune disease. More particularly, the method may comprise the steps of (a) providing a... Agent: The Board Of Regents Of The University Of Texas System

20140371130 - Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins: The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins.... Agent: The Hospital For Sick Children

20140371133 - Methods of treating chronic disorders with complement inhibitors: In some aspects, the invention provides methods of treating a subject in need of treatment for a chronic complement-mediated disorder. In some aspects, the invention provides methods of treating a subject in need of treatment for a Th17-associated disorder. In some aspects, the invention provides methods of treating a subject... Agent: Apellis Pharmaceuticals, Inc.

20140371134 - Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear: In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one... Agent:

20140371135 - High purity lipopeptides: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion... Agent: Cubist Pharmaceuticals, Inc.

20140371136 - Growth hormone polypeptides and methods of making and using same: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.... Agent: Amunix Operating Inc.

20140371138 - Inhibitors of hepatitis c virus replication: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production... Agent: Merck Sharp & Dohme Corp.

20140371137 - Preparation of pna-6-aminoglucosamine conjugates as antiviral agents: The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make... Agent:

20140371139 - Preparations containing amorphous emodepside: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.... Agent:

20140371140 - Insulin derivatives containing additional disulfide bonds: The present invention is related to insulin derivatives containing additional disulfide bonds and methods of making such.... Agent:

20140371141 - Insulin glargine/lixisenatide fixed ratio formulation: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.... Agent:

20140371142 - Myonectin (ctrp15), compositions comprising same, and methods of use: Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The... Agent:

20140371143 - New peptide inhibiting rankl-rank interaction and the use thereof: Provided are a peptide for inhibiting an interaction between an RANKL and an RANK consisting of an amino acid sequence of SEQ ID NO: 1 and a pharmaceutical composition for preventing or treating bone diseases including the peptide. The peptide consisting of an amino acid sequence of SEQ ID NO:... Agent:

20140371144 - Long-acting growth hormone and methods of producing same: Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing weight loss or body fat reduction, methods of increasing insulin-like growth factor (IGF-1) levels, and methods... Agent:

20140371145 - Scaffold for vascular endothelial cell migration: A scaffold for vascular endothelial cell migration includes a recombinant gelatin having an amino acid sequence derived from a partial amino acid sequence of collagen. A method for producing a blood vessel uses this scaffold.... Agent:

20140371146 - Glycoprotein hormone long-acting superagonists: This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein... Agent:

20140371147 - Combination of a prostaglandin receptor agonist and an mc1r receptor agonist for the treatment and/or prevention of pigmentation disorders: A combination of compounds is described for the treatment and/or prevention of skin conditions linked to hypopigmentation. Also described, is a combination product that includes at least one prostaglandin receptor agonist and at least one MC1R receptor agonist, as a medicament for use simultaneously, separately or spread out over time... Agent:

20140371148 - Peptide-peptidase inhibitor conjugates and methods of using same: Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any... Agent: Amylin Pharmaceuticals, LLC

20140371149 - Scarring reducing wound treatment: The present invention refers to the use of hemoglobin or myoglobin charged with a non-oxygen ligand for improved scarring of wounds.... Agent:

20140371150 - Peptides targeting receptor activator of nuclear factor - kappa b (rank) and their applications: The present invention relates to a polypeptide for use as a medicament in the treatment and/or prevention of a disease wherein the RANKL-RANK signaling pathway is involved, in particular a bone resorptive disease.... Agent:

20140371151 - Use of liposomal wnt composition to enhance osseointegration: Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain... Agent:

20140371152 - Amyloid beta-protein-specific production-inhibiting polypeptide: This object can be achieved by a polypeptide having the amino acid sequence represented by any one of SEQ ID NOs: 1, 13, 14, and 22, that binds to the N-terminal region of βCTF; a γ-secretase activity inhibitor containing the polypeptide; β-secretase activity inhibitor; Aβ protein production inhibitor; and an... Agent: The Doshisha

20140371153 - Method for administering omega-conopeptide: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its... Agent:

20140371154 - Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present... Agent: Trustees Of Tufts College

20140371155 - Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof: The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis. The peptides of the present disclosure include peptides comprising SEQ ID NOs: 1-4 which promote angiogenesis and cell proliferation. Further, the anti-angiogenic compounds of the present... Agent: Trustees Of Tufts College

20140371156 - Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells: An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and administering to the cells a compound, including an HDM-2 targeting component and a cytotoxic component attached to the HDM-2 targeting... Agent: The Research Foundation Of State University Of New York

20140371157 - Methods of downregulating translocated oncogene expression using bromodomain inhibitors: Disclosed herein are novel methods and compositions useful for inhibiting interaction between a bromodomain protein and an immunoglobulin (Ig) regulatory element. The methods and compositions are particularly useful for downregulating expression of an oncogene translocated with an Ig locus, as well as for treating a cancer (e.g., hematological malignancy) characterized... Agent: Whitehead Institute For Biomedical Research

20140371158 - Beauvericin compositions and methods thereof for inhibiting the hsp90 chaperone pathway: Methods of inhibiting the Hsp90 chaperone pathway including contacting one or more target cells with an effective amount of a naturally occurring beauvericin, a synthetic beauvericin, or a derivative, analog or prodrug, or a pharmacologically active salt thereof to reduce, decrease, or inhibit the Hsp90 chaperone pathway in the cells... Agent:

20140371159 - In vitro method for modifying the depletion profile of treg cells present in a total splenocyte population of a biological sample by means of the isolation, culturing and exposure thereof to an atp and polymixin b medium: In vitro method to modify the deplexion profile of Treg Cells present in a total splenocyte population of a biological sample comprising isolating, cultivating and submitting the splenocyte at a ATP medium and polymyx B, where the splenocytes at concentrations of Polymyxin B in the range 0.1 μg/ml to 100... Agent: Universidad De Santiago De Chile

20140371160 - Novel alpha-1 antitrypsin variant, preparation method thereof and use thereof: A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t1/2) and the area under blood drug concentration vs. time curve (AUC)... Agent: Alteogen, Inc

20140371161 - Novel peptides and methods and uses thereof for preventing retinal disorders: The present disclosure relates to methods and uses of C-terminal peptides for inhibiting neuronal cell death or dysfunction, such as retinal ganglion cell death or dysfunction, treating retinal degenerative disorders, stroke, CNS and PNS insults. The disclosure also relates to the C-terminal peptides, fusion proteins and compositions thereof.... Agent: Governing Council Of The University Of Toronto

20140371162 - Combination therapy comprising sglt inhibitors and dpp4 inhibitors: The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.... Agent:

20140371163 - Combination therapy for acne vulgaris comprising administration of adapalene 0.3% gel and clindamycin/benzoyl peroxide gel: A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®.... Agent: Galderma Research & Development

20140371164 - Synergistic combination comprising avermectins and a nsaid for tumor inhibition: The present invention includes a composition comprising an effective amount of an avermectin compound, and an effective amount of an imidazole antifungal compound, and/or an effective amount of non-steroidal anti-inflammatory drug (NSAID) or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treating urothelial, colorectal,... Agent:

20140371165 - Identification of nsc23925 isomers to reverse multidrug resistance in human cancers: This disclosure features optically active stereoisomers of (2-(4-methoxy)quinolin-4-yl)(piperidin-2-yl)methanol that reduce drug resistance, compositions containing the same, and methods of using and preparing the same.... Agent: The General Hospital Corporation

20140371166 - Antibiotic composition for inhalation and irrigation: An antibiotic composition for the treatment of bacterial infections, especially in the respiratory tract is provided. The antibiotic composition may include a mixture of gentamicin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407... Agent: Professional Compounding Centers Of America

20140371293 - Amine cationic lipids and uses thereof: The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g.,... Agent: Dicerna Pharmaceuticals, Inc.

20140371297 - Anti-connexin compounds targeted to connexins and methods of use thereof: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell... Agent:

20140371294 - Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities: Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.... Agent: Pangu Biopharma Limited

20140371292 - Method for the controlled intracellular delivery of nucleic acids: The present invention relates to a method for the controlled intracellular delivery of nucleic acid molecules into one or more target cells, in particular tumor cells, the method comprising: providing a polymeric complex formed between one or more nucleic acid molecules to be delivered and one or more cationic carrier... Agent: Ludwig-maximilians-universitat Munchen

20140371295 - Methods and compositions to protect aquatic invertebrates from disease: Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal.... Agent:

20140371296 - Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (malat-1) expression: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is... Agent: Isis Pharmaceuticals, Inc.

20140371300 - Pharmaceutical composition for treating cancer: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and... Agent:

20140371298 - Prevention and treatment of nosema disease in bees: Compositions and methods for reducing susceptibility and enhancing tolerance to Nosema disease (Nosemosis) using RNA interference technology, and more particularly, prevention and treatment of Nosema infections in honeybees by feeding of Nosema-specific dsRNA.... Agent:

20140371301 - Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent:

20140371299 - Use of apoptosis-specific elf-5a sirna to down regulate expression of proinflammatory cytokines to treat sepsis: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for down regulating pro-inflammatory cytokines in a mammal by administering siRNA against eIF-5A1 to the mammal to treat/prevent sepsis and/or hemorrhagic shock.... Agent: Senesco Technologies, Inc.

20140371302 - Modified mrnas encoding cell-penetrating polypeptides: This invention relates to modified nucleic acid compositions encoding cell-penetrating polypeptides to provoke an innate immune response in a cell and methods of delivering protein-binding partners to target cells.... Agent:

20140371167 - Uridine nucleoside derivatives, compositions and methods of use: This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease)... Agent: Tufts University

20140371168 - Oligomer-nucleoside phosphate conjugates: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble, non-peptidic oligomer. The conjugates of the invention, when administered by any of a number administration routes, exhibits advantages over previously administered compounds.... Agent: Nektar Therapeutics

20140371169 - Aqueous iron carbohydrate complexes, their production and medicaments containing them: A water soluble iron carbohydrate complex obtainable from an aqueous solution of iron(III) salt and an aqueous solution of the oxidation product of one or more maltrodextrins using an aqueous hypochlorite solution at a pH-value within the alkaline range, where, when one maltodextrin is applied, its dextrose equivalent lies between... Agent:

20140371170 - Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid: Disclosed are pharmaceutical compositions containing clodronic acid and hyaluronic acid or their salts as active constituents, mixed with suitable vehicles.... Agent:

20140371171 - Aqueous lock composition comprising ethanol and a polysaccharide anticoagulant: The invention relates to an aqueous lock composition comprising a compound selected from the polysaccharide anti-coagulants and ethanol, and a method for locking an intravascular device implanted in a patient comprising the introduction of said composition into the device.... Agent:

20140371172 - Process for the production of nano-fibrillar cellulose suspensions: The present invention relates to a process for the production of suspensions of nano-fibrillar cellulose by providing cellulose fibres and at least one filler and/or pigment; combining the cellulose fibres and the at least one filler and/or pigment; and fibrillating the cellulose fibres in the presence of at least one... Agent: Omya International Ag

20140371173 - Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk: A prebiotic formulation for oral administration to a human comprising 2′-fucosyllactose, 3′-sialyllactose and 6′-sialyllactose, and a method for modulating or stimulating the growth of Bifidobacteria in the gut. The formulation may be an infant formula.... Agent: Nestec S.a.

20140371174 - Effervescent dosage form: An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can... Agent:

20140371176 - Cyclopropylamines as lsd1 inhibitors: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.... Agent:

20140371175 - Inhibitors of arginase and their therapeutic applications: i

20140371177 - Treatment of cancer, inflammatory disease, and autoimmune disease: A method of treating cancer, inflammatory disease, and autoimmune disease by administering to a subject in need thereof an effective amount of one or more 1,5-dipenylpenta-1,4-dien-3-one compounds. The compounds feature either or both of the phenyl rings being substituted with hydroxyl, diethyl(2-alkoxyethyl)amine, 1-(2-alkoxyethyl)piperidine, sulfonate, phosphinate, or phosphate.... Agent:

20140371178 - Pest control composition: Disclosed is a pest control composition comprising at least one pyripyropene derivative of formula (I) or agriculturally and horticulturally acceptable salt thereof and at least one other pest control agent as active ingredients. The combined use of the two ingredients can provide a better insecticidal effect.... Agent:

20140371179 - Methods and compositions for treating esophageal diseases: Compositions and methods for treating esophageal diseases are disclosed. More specifically, these methods may refer to the treament of esophageal varices and eosinophilic esophagitis using an oral suspension drug for humans. The oral suspension drug may include poloxamer f127 used as vehicle and budesonide as a corticosteroid. Poloxamer oral suspension... Agent: Professional Compounding Centers Of America

20140371182 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent:

20140371183 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent:

20140371184 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent:

20140371185 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent:

20140371181 - Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens: Prodrugs of C-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (AR), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such... Agent:

20140371180 - Process for purification and isolation of estrogens: The present application relates to a method for obtaining a mixture of estrogens from the pregnant mare's urine.... Agent:

20140371188 - Compositions and methods for inhibiting muscle atrophy and inducing muscle hypertrophy: In an aspect, the invention relates to compositions, methods, and kits for inhibiting or preventing skeletal muscle atrophy or inducing muscle hypertrophy by providing to an animal an effective amount of a composition comprising a Gadd45a and/or Cdkn1a inhibitor and an androgen and/or growth hormone elevator or an androgen and/or... Agent: University Of Iowa Research Foundation

20140371187 - Semi-solid delivery vehicle and pharmaceutical compositions: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.... Agent: Heron Therapeutics, Inc.

20140371186 - Testosterone combined with anastrozole injection solutions: Compositions and methods for testosterone booster injection solutions (TBIS) that includes testosterone cypionate in synergistic combination with anastrozole are disclosed. Disclosed TBIS may be administered for treating testosterone deficiency. Disclosed TBIS is an intramuscular injection. The therapeutic dosage and protocol varies, according to the individual person. Different formulations may be... Agent: Professional Compounding Centers Of America

20140371189 - Testosterone replacement therapy in animals, including dogs: A method of treating an animal which does not naturally produce sufficient quantities of testosterone includes periodically administering a testosterone to the animal. The method includes conducting an initial examination of the animal; determining a testosterone level of the animal; administering a testosterone to the animal; determining the testosterone level... Agent: David Bieber Consulting, LLC

20140371190 - Farnesoid x receptor modulators: m

20140371191 - Oromucosal liquid estradiol compositions: The present invention relates to low dose estradiol solutions for oromucosal administration suitable in replacement therapy or suppletion of low estradiol levels and also for preventing, alleviating or treating symptoms associated with low endogenous levels of estradiol in female subjects.... Agent:

20140371192 - Alpha-form zinc-phthalocyanine nanowires having enhanced water solubility and water dispersibility, composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, and method for preparing same: The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the... Agent: Pohang University Of Science And Technology Industryacademy Cooperation Corps

20140371193 - Organometallic complexes as therapeutic agents: This invention comprises salophene-based metallic complexes. Included are metal-chelating analogues, and method of their preparation and use. These analogues have therapeutic activity including anticancer activity.... Agent: Women & Infants' Hospital

20140371194 - Methods for the treatment of bacterial infections: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.... Agent:

20140371197 - 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and in cosmetics: i

20140371200 - Alkene azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators: The present invention relates to alkene azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20140371199 - Bicyclic heterocyclic derivatives as mnk1 and mnk2 modulators and uses thereof: The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation... Agent: Agency For Science, Technology And Research

20140371198 - Novel compounds useful for the treatment of metabolic and inflammatory diseases: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative... Agent:

20140371196 - Diamino heterocyclic carboxamide compound: Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present... Agent: Kotobuki Pharmaceutical Co., Ltd.

20140371195 - Inhibitors of histone demethylases: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of... Agent:

20140371204 - 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives: The invention relates to compounds of Formula (I) wherein ring A, X, (R1)n, R2, R3, R4, R4′, R5, n, and p are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.... Agent:

20140371201 - Bicyclic sulfonamide compounds as sodium channel inhibitors: e

20140371202 - Indazole compounds as kinase inhibitors and method of treating cancer with same: The present teaching provide indazole compounds represented by Structural Formulae (I) or (I′) or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof as protein kinase inhibitors, such as TTK protein kinase, polo-like kinase 4 (PLK4) and Aurora kinases having anticancer activity against breast... Agent: University Health Network

20140371203 - Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors: The present invention provides compounds of formula (I): (Formula (I); wherein A, R1, R2, R3I, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases... Agent:

20140371205 - Substituted pyrimidines for the treatment of diseases such as cancer: e

20140371206 - Bromodomain inhibitors and uses thereof: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Agent: Constellation Pharmaceuticals, Inc.

20140371207 - Chemokine receptor antagonists and methods of use thereof: e

20140371208 - Methods of treating disease-induced ataxia and non-ataxic imbalance: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.... Agent:

20140371209 - S1p modulating agents: Compounds of formula (I) or (II) can modulate the activity of SIP receptors.... Agent:

20140371210 - Methods and compositions for rapid transbuccal delivery of active agents: A method of rapid transbuccal delivery of an active agent into the bloodstream is provided. The method can include providing a pharmaceutical composition comprising the active agent, resin and a volatile solvent and, optionally, water. In some embodiments, the method achieves a Tmax 60 minutes or less, an onset of... Agent: Jaleva Pharmaceuticals, LLC

20140371211 - Piroxicam transdermal composition to treat plantar fasciitis: A transdermal composition and method to be used as a treatment for plantar fasciitis is provided. Transdermal composition may include a combination of about 2% w/w to about 5% w/w of piroxicam and about 95% w/w to about 98% w/w of a natural permeation enhancement (NPE) composition. The NPE composition... Agent: Professional Compounding Centers Of America

20140371212 - Bace inhibitors: t

20140371213 - 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators:

20140371214 - Inhibitors of histone demethylases: In which Q is selected from —CH═NR12, —W, —CH2NHR13, —CH═O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of... Agent:

20140371215 - 1-h-pyrrolo[2,3-b]pyridine derivatives: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gmbh

20140371218 - Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders: -

20140371216 - Purinone derivatives as hm74a agonists: The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.... Agent: Incyte Corporation

20140371217 - Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors: The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.... Agent: Dr. Reddy's Laboratories Ltd.

20140371219 - Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.... Agent: Hanmi Pharm. Co., Ltd

20140371221 - Quinoline compound composing 1,2,4-triazine-dione and use thereof: The present invention relates to a quinoline derivative represented by general formula (I) or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof wherein Ar, R1, R2, R3, X, Y and n have the meanings given in the description. The present invention also relates to the comparatively strong effect of... Agent:

20140371220 - Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors: The present invention is directed to novel piperidinyl-pyridazinyl derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.... Agent: Janssen Pharmaceutica Nv

20140371222 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Synta Pharmaceuticals Corp.

20140371223 - Novel triazinedione derivatives as gabab receptor modulators: The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating... Agent: Addex Pharma S.a.

20140371224 - Novel compounds and compositions for treatment of breathing control disorders or diseases: The present invention includes compounds, and compositions comprising the same, that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering... Agent:

20140371225 - Pyridazinone compounds and methods for the treatment of cystic fibrosis: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to a patient in need thereof:... Agent: Flatley Discovery Lab

20140371226 - 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy-quinazoline-6-yloxy]-1,4-diaza-spiro[5.5]undecane-5-one dimaleate, use thereof as a medicament and method for the production thereof: e

20140371227 - Kappa opioid receptor effectors and uses thereof: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.... Agent: University Of Kansas

20140371229 - New therapeutic approaches for treating parkinson's disease: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s),... Agent:

20140371228 - Novel therapeutic agents: The present invention includes a method of treating or preventing a disease or disorder such as a mycobacterial infection, a Gram-positive bacterium infection, a yeast infection, an inflammatory condition, an auto-immune disorder and/or a proliferative disorder in a subject in need thereof. The method comprises administering to the subject a... Agent:

20140371230 - Heteroaryl derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent:

20140371231 - Methods of treating dyskinesia and related disorders: The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders.... Agent:

20140371232 - Cajanine structure analogous compound, preparation method and use: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the... Agent:

20140371233 - Compositions and methods for treating aß-modulated disease or disorder or improving cognition in a subject: The present invention provides compositions and methods for treating and preventing an Aβ-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits Aβ oligomer induced signaling and reduces or halts the... Agent: Yale University

20140371234 - Antifibrotic compounds and uses thereof: The present invention provides compounds having the general structural formula (I), and pharmaceutically acceptable derivatives thereof, as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases involving... Agent: Angion Biomedica Corp.

20140371236 - Agent for treatment of schizophrenia: The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,23,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily... Agent: Sumitomo Dainippon Pharma. Co., Ltd.

20140371235 - Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer: e

20140371237 - P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth: Provided are novel methods and compositions for the diagnosis, prognosis and treatment of leiomyomas, in particular uterine leiomyoma (UL). In addition, methods of identifying anti-tumor agents are described. Furthermore, novel methods and compositions are provided for the treatment of diseases characterized by an aberrant growth of mesenchymal stem cells and... Agent:

20140371238 - Compounds and methods for the treatment of cystic fibrosis: The invention relates to a compound of Formula I and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:... Agent: Flatley Discovery Lab

20140371239 - Menin-mll inhibitors and methods of use thereof: The present invention relates generally to compounds that inhibit the binding of menin and MLL or MLL fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with MLL oncoproteins (e.g.,... Agent:

20140371240 - Novel insecticidal aromatic amides: e

20140371241 - Tec family kinase inhibitor adjuvant therapy: Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.... Agent: Pharmacyclics, Inc.

20140371242 - Azathioprine oral suspensions and methods of use: Compositions of azathioprine oral suspensions are disclosed. Disclosed azathioprine oral suspensions may be used to administer azathioprine to subjects such as children and geriatric patients that may have difficulty in swallowing solid dosage forms. The disclosed azathioprine oral suspension may be used for treating autoimmune diseases such as rheumatoid arthritis,... Agent: Professional Compounding Centers Of America

20140371243 - Medical use of a dpp-4 inhibitor: The present invention relates to the use of a certain DPP-4 inhibitor along with angioplasty or stenting, and/or to its use for treating and/or preventing restenosis from angioplasty or stenting.... Agent: Boehringer Ingelheim International Gmbh

20140371244 - Method for treating prostate cancer by use of pharmaceutical composition containing a3 adenosine receptor agonist: The present invention relates to a method by use of a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less... Agent: Ewha University - Industry Collaboration Foundation

20140371245 - Novel derivatives of purinic and pyrimidinic antiviral agents and use thereof as potent anticancer agents: Novel N-acylated, O-acylated and (bis or tris)-N,O-acylated derivatives of purinic and pyrimidinic nucleoside analogs, pharmaceutical compositions containing same, and uses thereof for treating proliferative diseases or disorders are disclosed.... Agent:

20140371246 - Phosphatidylinositol 3-kinase inhibitors: or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of... Agent:

20140371247 - Selective and reversible inhibitors of ubiquitin specific protease 7: The present invention relates to quinazolin-4-one compounds of formula (I′), their process of preparation and uses thereof. These compounds are useful as selective and reversible inhibitors of ubiquitin specific proteases, particularly USP7, for treating e.g. cancer, neurodegenerative diseases, inflammatory disorders and viral infections.... Agent: Hybrigenics Sa

20140371248 - Small molecule activators of hslv protease for development of novel antimicrobials: HslVU is the proteasome-related system composed of HslV peptidase and HslU chaperone. It is involved in intracellular proteolysis. The presence of HslVU homologs in pathogenic microbes and its absence in human makes it an antimicrobial drug target. The functional HslVU complex forms when HslV dodecamer is flanked at both ends... Agent:

20140371249 - Crystal of a free tricyclic pyrazolopyrimidine derivative: To provide a crystal of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90. The present invention provides a crystal of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a medicament comprising the same, an anticancer agent comprising the same, and the like.... Agent: Daiichi Sankyo Company, Limited

20140371250 - Tricyclic compounds as modulators of tnf-alpha synthesis and as pde4 inhibitors: The present invention relates to chemical compounds of Formula (I) are as herein defined, pharmaceutical compositions, and methods of use in the treatment of conditions or disorders mediated by TNF-α or by PDE4, including but not limited to rheumatoid arthritis.... Agent:

20140371251 - Method of inhibiting dyrk1b: The present invention relates to a DYRK1B inhibitor for use in the treatment of cancer, wherein in said cancer and/or in cells of said cancer the hedgehog signaling pathway is activated, and in particular the activation of the hedgehog signaling pathway is independent of signaling by the G protein-coupled receptor... Agent: 4sc Discovery Gmbh

20140371252 - Indene derivatives as pharmaceutical agents: e

20140371253 - Cyclopamine analogs: The invention provides novel derivatives of cyclopamine having the following formula:... Agent: Infinity Pharmaceuticals, Inc.

20140371254 - Novel treatment of gefitinib-resistant non-small-cell lung cancer: The present invention discloses a method of preventing and treating Gefitinib-resistant non-small-cell lung cancer, comprising administering an effective amount of an alkaloid. A pharmaceutical composition comprising an alkaloid admixed with a pharmaceutical carrier for treating Gefitinib-resistant non-small-cell lung cancer is also disclosed therein.... Agent:

20140371255 - Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction,... Agent: Virginia Commonwealth University

20140371256 - Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and... Agent:

20140371257 - Pharmaceutical formulation containing gelling agent: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Agent:

20140371258 - Water-soluble polymer conjugates of topotecan: Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same.... Agent: Nektar Therapeutics

20140371259 - Compounds and methods for inhibition of ap endonuclease-1/redox factor-1 (hape1) activity: A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20140371260 - Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors: The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.... Agent: Merz Pharma Gmbh & Co. Kgaa

20140371261 - Indomethacin analogs for the treatment of castrate-resistant prostate cancer: Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have... Agent: Vanderbilt University

20140371262 - Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment: It is intended to provide a highly safe, orally administrable preventive and/or therapeutic agent for thrombosis and/or embolism that can be applied to a thrombosis and/or embolism patient with severe renal impairment. The present inventors have found that even for a thrombosis and/or embolism patient with severe renal impairment, use... Agent:

20140371263 - Compounds and methods for the treatment of cystic fibrosis: The invention relates to a compound of Formula I and methods of treating CFTR (cystic fibrosis transmembrane conductance regulator) mediated diseases, in particular cystic fibrosis, comprising the step of administering a therapeutically effective amount of a compound of Formula I or IA to a patient in need thereof:... Agent: Flatley Discovery Lab

20140371264 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.... Agent:

20140371265 - Compositions and methods for treatment: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Sarcode Bioscience Inc.

20140371266 - Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors: Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and gastrointestinal tract disorders.... Agent:

20140371267 - Ophthalmic composition with nitric oxide donor compound and method of forming and using same: The present invention is directed to the provision of ophthalmic compositions such as multi-dose, topical, ophthalmic compositions. The compositions include a nitric oxide (NO) donor compound.... Agent: Alcon Research, Ltd.

20140371268 - Biphenylcarboxamides as rock kinase inhibitors: The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and... Agent: Amakem Nv

20140371269 - Phenyl methanesulfonamide derivatives useful as mgat-2 inhibitors: The present invention provides compounds of Formula I or a pharmaceutical salt thereof, where the variables for R1, R2, and R3 are as described herein; methods of treating a condition such as hypertriglyceridemia; and processes for preparing the compounds.... Agent: Eli Lilly And Company

20140371270 - Novel acetic acid ester compound or salt thereof: e

20140371271 - Novel piperine derivatives and uses thereof: The present invention provides novel piperine derivatives. The present pharmaceutical or food composition containing a piperine derivative as an active ingredient is very effective in preventing or treating metabolic diseases including obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. Piperine derivatives of the present invention useful as pharmaceuticals compositions... Agent: Industry-academic Cooperation Foundation, Yonsei University

20140371272 - Therapeutic compounds: The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I) and therapeutic methods for treating cancer or treating autoimmune... Agent:

20140371273 - Polymorphs of perampanel: The present invention provides novel crystalline forms of perampanel, pharmaceutical compositions comprising same, methods for their preparation and uses thereof for treating seizures and epilepsy.... Agent: Mapi Pharma Ltd.

20140371274 - Bradykinin receptor antagonists and pharmaceutical compositions containing them: The present invention relates to novel compounds, their use in the prevention or treatment of symptoms and disorders associated with the bradykinin B1 pathway and pharmaceutical compositions containing them.... Agent:

20140371275 - Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.... Agent:

20140371276 - Trpm8 antagonists: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel... Agent:

20140371277 - Compositions for treating amyotrophic lateral sclerosis: The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.... Agent:

20140371278 - Benzoheterocyclic compounds and use thereof: Disclosed are compound of formula (I) and pharmaceutically accepted salts and prodrugs thereof, wherein each of R1, R2, R3, R4, R5, R6, X1 and X2 is as defined in the description. These compounds are protein kinases inhibitors, especially the inhibitors of Mek, which are useful in the treatment of cancers... Agent: Tianjin Binjiang Pharma, Inc.

20140371279 - Crystalline forms of azilsartan and preparation and uses thereof: The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J or form K.... Agent: Ruyuan Pharm Co., Ltd.

20140371280 - Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial atp production, and through induction of neuronal regeneration: e

20140371281 - Pesticidal mixtures: The present invention relates to pesticidal mixtures comprising a component A and a component B, wherein component A is a compound of formula (I) wherein B1, B2, B3, X1, X2, X3, X4, Y1, Y2, Y3 and R9 are as defined in claim 1 and component B is an insecticide. The... Agent: Syngenta Participations Ag

20140371282 - Controlled release pharmaceutical compositions with improved bioavailabililty: The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the... Agent:

20140371283 - Hydantoins that modulate bace-mediated app processing: In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form... Agent: Buck Institute For Research On Aging

20140371284 - Imidazolidinedione compounds and their uses: Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.... Agent: Hc Pharmaceutical Co., Ltd.

20140371285 - Therapeutic compounds and related methods of use: Salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Dosage forms and kits comprising salinomycin analogs and pharmaceutically acceptable compositions containing salinomycin analogs. Methods of using salinomycin analogs, pharmaceutically acceptable compositions, dosage forms, and kits for the treatment of proliferative diseases, e.g., cancer, or microbial infections in a subject... Agent:

20140371286 - De novo synthesis of bacteriochlorins: to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry,... Agent: North Carolina State University

20140371287 - Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-ethylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the... Agent:

20140371288 - Plant disease control composition: e

20140371289 - Composition for elimination of troublesome varmints: Composition for elimination of troublesome varmints comprises all the non-essential amino acids alanine, glycine, proline, serine, tyrosine, aspartic acid, asparagine, glutamic acid.... Agent: Determinants Of Metabolism Research Laboratory S.r.l.

20140371290 - Glycopyrrolate salts: Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed.... Agent: Dermira, Inc.

20140371291 - Serine racemase inhibitor: A novel serine racemase inhibitor exhibits sufficient activity and specificity. The serine racemase inhibitor includes one or more compounds selected from compounds respectively represented by the following general formulas [MM_1], [DR_1], [DR′_1], [LW_1], and [ED_1] as an active ingredient.... Agent:

20140371303 - Compositions and methods for glycemic control of subjects with impaired fasting glucose: Compositions and methods for providing anti-diabetic and anti-hyperlipidemia benefits to diabetic subjects currently on medication but not meeting recommended targets for blood glucose, HbA1c, blood pressure and total cholesterol.... Agent:

20140371304 - Method for suppressing tumorigenicity of stem cells: A method for suppressing tumorigenicity of stem cells in a mammalian subject, which comprises administering an effective amount of a fatty acid derivative and a method for suppressing tumorigenicity of stem cells of a mammalian subject, which comprises contacting said stem cell with an effective amount of a fatty acid... Agent: Sucampo Ag

20140371305 - Mupirocin antibiotic composition: An antibiotic inhalation or irrigation composition for the treatment of bacterial infections especially in the respiratory tract, is provided. The antibiotic inhalation or irrigation composition may include a mixture of mupirocin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by... Agent: Professional Compounding Centers Of America

20140371306 - Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases: The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing... Agent: Universit&#xc4 T Innsbruck

20140371307 - Sirt 1 activator including syringaresinol: The present invention relates to a compound of Formula 1, and an SIRT 1 activator including, as an active ingredient, derivatives thereof or pharmaceutically acceptable salts thereof. The present invention also relates to a composition including the SIRT 1 activator for detoxification, for the improvement of metabolic disorders, for the... Agent: Amorepacific Corporation

20140371308 - Hypotensive lipid-containing biodegradable intraocular implants and related methods: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.... Agent:

20140371309 - Ophthalmic solution: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.... Agent: Sucampo Ag

20140371310 - Mandelic acid condensation polymers: Disclosed herein are compounds and compositions useful for reducing the risk of infection. In particular, disclosed herein are mandelic acid condensation polymers, compositions comprising such compounds, processes for producing such compounds, and methods of using such compounds.... Agent:

20140371311 - Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene... Agent: Korea Research Institute Of Bioscience And Biotechnology

20140371312 - Composition for preventing the occurrence of cardiovascular event in multiple risk patient: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring... Agent:

20140371313 - Cyclohexane-1,3-diones for use in the treatment of amyotrophic lateral sclerosis: The present invention relates to the identification of provided cyclohexane-1,3-diones (CHD compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided CHD compounds.... Agent:

20140371314 - Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof: This invention relates to deuterated tetramethyl dioic acids, compositions comprising them and uses thereof in the treatment of Metabolic Syndrome and any diseases, disorders or symptoms associated therewith.... Agent:

20140371315 - Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids: A composition and method for supplementing food, nutrition, and diet systems with omega-6 to omega-3 balanced oils comprising a synergistic blend of at least two oils. The composition further comprises a synergistic blend of long chain omega-3 oil as a means to further increase the nutritional value. The composition provides... Agent: Omega Foods, LLC

20140371316 - Derivatives of phenoxyisobutyric acid: The present invention provides a process for the synthesis of substituted phenoxymethylpropiomc acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).... Agent:

20140371317 - Silicone resin emulsions: The present disclosure relates to compositions comprising: i) an aqueous silicone emulsion comprising; A) 0.5 wt % to 95 wt % of a silicone gum, resin, or PSA, B) 0.1 to 90 wt % of an ethylene oxide/propylene oxide block copolymer, and sufficient amount of water to sum all ingredients... Agent: Dow Corning Corporation

20140371318 - Orally-disintegrating formulations of flurbiprofen: The present invention relates to an orally-disintegrating pharmaceutical formulation, which is characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.... Agent:

20140371319 - Novel indanesulfamlde derivatives: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.... Agent: Eisai R&d Management Co., Ltd.

20140371320 - Compositions and methods for stimulating hair growth: wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human... Agent: Allergan, Inc.

20140371321 - Novel process for concentrating spilanthol and/or isomers and/or homologues thereof: e

20140371322 - Phenoxybenzamine transdermal composition: A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about... Agent: Professional Compounding Centers Of America

20140371323 - Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol: p

20140371324 - Inhibitors of cognitive decline: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods of treating, inhibiting, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods... Agent: Cognition Therapeutics, Inc.

20140371325 - Nitisinone for treatment of oculocutaneous/ocular albinism and for increasing pigmentation: A method is provided for the treatment of vision problems in a subject suffering from one of various forms of albinism, including, for example, oculocutaneous albinism types OCA1a and OCA1b, as well as ocular albinism type 1, resulting from mutations in the GPR143 gene, as well as the OCA2, OCA3... Agent:

20140371326 - Food composition for preventing obesity, pharmaceutical composition for treating obesity, and animal medicine for treating obesity, containing gingernone a: Disclosed is a composition comprising gingerenone A as an active ingredient. The composition includes a food composition for preventing obesity, a pharmaceutical composition for treating obesity and a medicine for treating animal obesity. Since the composition includes gingerenone A, which inhibits expression of the important transcriptional factors C/EBPα and PPARγ,... Agent: Snu R&db Foundation

20140371327 - Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof: Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid... Agent:

20140371328 - Novel compounds: The present invention relates to topical compositions comprising resveratrol in a liquid crystal gel network formed by a phosphate ester surfactant and a co-emulsifier. The present invention also relates to the process to make such compositions.... Agent: DsmIPAssets B.v.

20140371329 - Buffered oxygen therapeutic: An oxygen therapeutic composition, which includes a perfluorocarbon material having a boiling point of about 4 degrees Celsius to about 60 degrees Celsius, a lipid; a viscosity modifier; a buffer.... Agent:

20140371330 - Novel co-modified organopolysiloxane, and treatment agent and external use preparation comprising the same: A co-modified organopolysiloxane having a viscosity at 25° C. of not more than 1,500 mPa·s, a group that has a siloxane dendron structure, a hydrophilic group, and expressed by the following general formula (1): R1aR2bL1cQdSiO(4-a-b-c-d)/2 (1). The invention also relates to a powder treatment agent, a powder in oil dispersion,... Agent:

20140371331 - Surfactant composition: The present invention provides a surfactant composition containing a polyglycerol alkyl ether which is capable of exhibiting a high emulsification performance for silicone oils compounded in cosmetics, detergents, etc., by using a natural alcohol derived from oils and fats as a raw material thereof, a process for producing the surfactant... Agent:

20140371332 - Method for producing vesicle composition: Provided is a method for producing a vesicle composition having an aqueous phase as a continuous phase, containing: an oil phase-preparation step for dissolving an oil phase containing components (A) to (D) at a temperature of equal to or higher than melting point of the oil phase, the components (A)... Agent:

20140371333 - Lecithin-organogelling agent: An organogelling agent for forming reverse worm-like micelles having high safety to living bodies and the environment, favorable feel of use, and a high gelating ability and a thickened gel composition comprising the organogelling agent are provided. Lecithin and ascorbic acid or an ascorbic acid derivative act as an organogelling... Agent:

  
12/11/2014 > 157 patent applications in 120 patent subcategories.

20140364358 - Method for preventing and treating hyperpermeability: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of hyperpermeability of epithelial... Agent: Apeptico Forschung Und Entwicklung Gmbh

20140364359 - Compositions and methods for treating cancer and inflammation-related dieseases and conditions: The invention provides di-peptide conjugated antitumor agents, pharmaceutical compositions and methods for preparation and use thereof for treating various cancer and inflammation-related diseases and conditions. The present invention addresses the shortcomings of the existing anti-tumor and anti-inflammatory drugs, particularly in that the anti-tumor agents of the invention that selectively kill... Agent:

20140364360 - Glycosaminoglycans for chemokine drug delivery: A pharmaceutical composition for sustained release of a chemokine is described that includes a polymer bonded to a sulfated glycosaminoglycan and loaded with a chemokine having affinity for the sulfated glycosaminoglycan. The pharmaceutical composition can be used in a method for providing sustained release of a chemokine to subject by... Agent:

20140364361 - High protein liquid enteral nutritional composition: The present invention relates in general to a shelf-stable liquid enteral composition for providing nutrition, either as a supplement, or as a complete nutrition, with a high protein content of a non-hydrolysed globular protein, in particular a whey protein.... Agent: N.v. Nutricia

20140364362 - Therapeutic agents comprising insulin amino acid sequences: The present invention relates in part to agents which provide slow absorption from an injection site. In some embodiments, the pharmaceutical compositions comprises an insulin amino acid sequence and an amino acid sequence that provide slow absorption from an injection site, such as, for example, an amino acid sequence that... Agent:

20140364363 - Glypican-4 based compositions and methods for treating and diagnosing insulin resistance: Provided herein are methods for increasing insulin sensitivity in a subject. A method may comprise administering to a subject in need of increased insulin sensitivity a therapeutically effective amount of a glypican-4 agent. Also provided herein are methods for determining whether a subject is or is likely to become insulin... Agent:

20140364364 - Compounds for use in treatment of mucositis: The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.... Agent:

20140364366 - Compositions and methods for treating heart failure: The present invention provides methods for treating chronic heart failure patients using the medication comprising neuregulin. The methods comprise first performing a companion diagnostic test of each patient before treatment; and then providing a suitable treatment to the patient according to the results of the companion diagnostic test. When the... Agent:

20140364365 - Mask for skin care: A mask for skin care includes a fiber substrate, wherein the fiber substrate is woven or nonwoven, and includes modified fibers, and the modified fibers are cellulose fibers with at least one hydrophilic functional group grafted on. The grafted ratio of the modified fibers is in the range from 5%... Agent: Far Eastern New Century Corporation

20140364367 - Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener: This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other... Agent: Sedogen, LLC

20140364368 - Stimulus responsive nanocomplexes and methods of use thereof: The present invention provides stimulus responsive nanocomplexes comprising a masking moiety, e.g., a peptide, and a therapeutic moiety, e.g., an anti-coagulant. The invention also provides methods for treating or preventing a condition, such as a hypercoagulable state, e.g., blood clotting disorders or a cardiovascular disease, in a subject.... Agent:

20140364369 - Use of chemically modified heparin derivates in sickle cell disease: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.... Agent:

20140364370 - Combination therapies using cyclosporine and aromatic cationic peptides: The invention provides compositions and methods for preventing or treating an ischemia-reperfusion injury, such as occurs during acute myocardial infarction and organ transplant in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide or a pharmaceutically acceptable salt thereof, and one or... Agent: Stealth Peptides International, Inc.

20140364371 - Direct drug delivery system based on thermally responsive biopolymers: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent)... Agent:

20140364372 - Regeneration and repair of mesenchymal tissue using amelogenin: A method of treating an injury to hyaline cartilage in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of amelogenin.... Agent:

20140364373 - Novel enteric combination therapy: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers' diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor... Agent:

20140364374 - Amino acid sequence for inhibiting ptx3 to treat nasopharyngeal carcinoma: The invention relates to an amino acid sequence for inhibiting PTX3 to treat nasopharyngeal carcinoma. It can be used to inhibit PTX3 from promoting the migration and invasion of nasopharyngeal carcinoma cells, promoting angiogenesis and inhibiting macrophage phagocytosis to further treat nasopharyngeal carcinoma.... Agent: National Cheng Kung University

20140364375 - Combination therapy with peptide epoxyketones: The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent.... Agent:

20140364376 - Cell-penetrating peptides: The invention relates to a cell-penetrating peptide, optionally linked to a pro-apoptotic peptide, useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.... Agent:

20140364377 - Use of peptide epoxyketones for metastasis suppression: The invention provides a method of repressing metastasis of a cancer compromising the administration of a peptide epoxyketone proteasome inhibitor. Furthermore, the method can be performed in combination with the administration of one or more additional therapeutics.... Agent:

20140364378 - Method and pharmaceutical composition for hair growth: The present disclosure relates to a method and a pharmaceutical composition for hair growth. The pharmaceutical composition includes a hair growth peptide (HGP) which includes all or part of the amino acid sequence SEQ ID No: 1. The method includes administering a hair growth peptide (HGP) which includes all or... Agent:

20140364379 - Two part formulation system for ophthalmic delivery: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the... Agent: Allergan Inc.

20140364380 - Lipopeptide compositions and related methods: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.... Agent: Cubist Pharmaceuticals, Inc.

20140364381 - Wound dressings with enhanced gas permeation and other beneficial properties: A wound dressing comprises a wound dressing substrate including one or more of gas vesicles, rhamnolipids, and sophorolipids. The wound dressing can be fabric-based or hydrogel-based. Methods for producing a wound dressing are also provided.... Agent:

20140364382 - Composition for inhibiting liver function deterioration, containing citrus peel extract or narirutin as active ingredient, and method for extracting narirutin from citrus peel: The present invention relates to a pharmaceutical composition for treating liver diseases, containing a narirutin extract of citrus peel extract or narirutin as an active ingredient. The extract or narirutin decreases cholesterol levels and fat levels in liver tissue, and thus can be utilized as a composition or food for... Agent: Korea Food Research Institute

20140364383 - Methods and compositions for applying pharmacologic agents to the ear: Methods and materials useful for applying pharmacologic agents to the ear are described. The methods involve delivering a composition that contains at least one viscogenic agent and at least one pharmacologic agent to the epidermal surface of the tympanic membrane via the ear canal. The composition is delivered to the... Agent: Regents Of The University Of Minnesota

20140364384 - Medication adherence monitoring system: The present invention relates to the detection of markers in exhaled breath, wherein the detection of the presence or absence of the marker(s) in exhaled breath is used to assess various clinical data, including patient adherence in taking the medication and patient enzymatic (metabolic) competence in metabolizing the medication. An... Agent: University Of Florida Research Foundation, Inc.

20140364385 - Forazolines, compositions thereof and uses thereof: e

20140364386 - Small molecule compounds that control plant- and insect-pathogenic nematodes: The present invention relates to methods of modifying nematode behavior using certain isolated modulator compounds. Also disclosed are methods of promoting or inhibiting reproduction in a nematode population, methods of promoting or inhibiting nematode aggregation at a first location, and methods of treating or preventing parasite infection of a plant.... Agent: Boyce Thompson Institute For Plant Research

20140364387 - Methods and systems for modulating hormones and related methods, agents and compositions: Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.... Agent:

20140364483 - Alternative splicing variants of genes associated with prostate cancer risk and survival: Disclosed are novel splicing variants of the genes associated with prostate cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. The disclosure also relates risk assessment, detection, diagnosis, or prognosis of prostate cancer. More specifically, this disclosure relates to the detection of... Agent:

20140364484 - Combination therapy for treating hearing and balance disorders: The present application relates to combinations of inhibitors directed at down-regulation of genes associated with hearing loss including HES1, HES5, HEY2, CDKN1B and NOTCH1, exhibiting a beneficial effect and useful in treating or attenuating hearing loss, treating balance impairment, promoting the replacement, regeneration, or protection of otic (sensory) hair cells... Agent: Quark Pharmaceuticals, Inc.

20140364485 - Methods and compositions for the treatment of cancer: Some embodiments of the present invention relate to agents and compositions for treating cancer. More embodiments include agents and compositions for modulating the activity of the Hedgehog pathway.... Agent: University Of South Alabama

20140364482 - Reduced size self-delivering rnai compounds: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.... Agent: Rxi Pharmaceuticals Corporation

20140364481 - Rna chimeras in human leukemia and lymphoma: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent RNA fusions as diagnostic markers and clinical targets for leukemia.... Agent: The Regents Of The University Of Michigan

20140364480 - Rnai-mediated inhibition of igf1r for treatment of ocular angiogenesis: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.... Agent: Alcon Research, Ltd.

20140364487 - New c5a binding nucleic acids: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′ AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3′ [SEQ ID NO: 61], wherein n1 is U or... Agent:

20140364489 - Pharmaceutical composition producing antioxidant, antimicrobal, antitoxic protein - human lactoferrin, production process and therapeutic method.: The pharmaceutical composition producing the antioxidant, antimicrobal, antitoxic protein—human lactoferrin in which the therapeutic effect is achieved as a result of the antioxidant, antimicrobal, antitoxic protein—human lactoferrin on the human body different in what it contains human adenovirus 5 genome based non-replicating nanoparticles with the human lactoferrin gene insert expressing... Agent:

20140364486 - Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases: The present invention provides isolated promoters, transgene expression cassettes, vectors, kits, and methods for treatment of genetic diseases that affect the cone cells of the retina.... Agent:

20140364488 - Rpgrip1 gene therapy for leber congenital amaurosis: This invention relates to methods for treating subjects with vision loss due to advanced Leber Congenital Amaurosis (LCA), e.g., LCA6, which is due to loss-of-function mutations in the gene encoding the retinitis pigmentosa GTPase regulator interacting-protein-1 (RPGRIP1) protein.... Agent:

20140364388 - Method for inducing hepatocyte proliferation and uses thereof: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR... Agent:

20140364389 - Combination therapy: The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are... Agent: Japan Tobacco Inc.

20140364390 - Xyloglucan-based compositions for the treatment of gastrointestinal disorders: Described herein are compositions including xyloglucans as an active ingredient useful in the treatment of gastro-intestinal disorders or of disorders originating from the gastro-intestinal system and transferred to other systems, such as the genitourinary system. The compositions may have xyloglucans or an extract containing xyloglucans, and may further include other... Agent: Novintethical Pharma, Sagl

20140364391 - Immobilization of an active agent on a substrate using compounds including trihydroxyphenyl groups: The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, providing a substrate, contacting the substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated substrate, and contacting the trihydroxyphenyl-treated substrate with an active agent, thereby immobilizing the... Agent: Northwestern University

20140364392 - Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a... Agent: Novartis Ag

20140364394 - Novel liquid organopolysiloxane and uses thereof: A liquid organopolysiloxane having fluidity at least 100° C., a silicon-bonded glycerin derivative group, and a crosslinked structure comprising a carbon-silicon bond at the crosslinking portion.... Agent:

20140364395 - Pyranyl aryl methyl benzoquinolinone m1 receptor positive allosteric modulators: which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds... Agent:

20140364393 - Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors: The present invention is directed to novel piperidinyl-carboxamide derivatives, pharmaceutical compositions containing them and their use as inhibitors of SCD1, useful in the treatment of obesity, type-II diabetes and other related metabolic disorders.... Agent:

20140364396 - Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors: The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases.... Agent:

20140364397 - Acyclic nucleoside phosphonate diesters: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.... Agent:

20140364398 - C-linked hydroxamic acid derivatives useful as antibacterial agents: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.... Agent: Pfizer Inc.

20140364400 - Esters for treatment of ocular inflammatory conditions: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of... Agent:

20140364399 - Phospholipid compositions enriched for palmitoleic, myristoleic or lauroleic acid, their preparation and their use in treating metabolic and cardiovascular disease: The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R1 and R2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a... Agent: Omega Protein Corporation

20140364401 - Antispasmodic 1,2-diols and 1,2,3-triols: The present invention is directed to pharmaceutical compositions comprising antispasmodic C4-C8aliphatic-1,2-diols and C4-C8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid. Administration of the... Agent: Prima Innovations, LLC

20140364402 - Assay for screening compounds that selectively decrease the number of cancer stem cells: The present invention provides, inter alia, a method for identifying an agent that selectively decreases the number of cancer stem cells (CSCs). This method includes (a) contacting a CSC from a population of cells with a candidate agent; and (b) determining whether the candidate agent reduces the survival or growth... Agent: The Rogosin Institute

20140364403 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent:

20140364404 - Articles and methods of treating vascular conditions: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.... Agent:

20140364405 - Treatment of seborrhoea: A method for the treatment of seborrhoea in a patient comprises administering to the patient an effective amount of (24RS) or (24S) scymnol, an ester thereof or a pharmaceutically acceptable salt of a said ester, or of (24R) scymnol.... Agent: Mcfarlane Marketing (aust.) Pty. Ltd.

20140364406 - Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux: One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free... Agent:

20140364407 - Medical or therapeutic application of a composite material of ruthenium with a nitrosyl ligand: A medical or therapeutic application of a composite material of ruthenium with a nitrosyl ligand. Application for a medical or therapeutic treatment of a composite material of ruthenium with a nitrosyl ligand irradiated in a spectral range capable of releasing the nitrosyl ligand, i.e., the ultraviolet or visible or near-infrared... Agent: Centre National De La Recherche Scientifique - Cnrs

20140364410 - Pyrazolopyrimidine compounds as kinase inhibitors: The present disclosure provides compounds of Formula (IA) and/or pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BTK, and are potentially useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer, inflammatory diseases such as arthritis, and the like. Also provided are... Agent:

20140364409 - Substituted pyrazolo[3',4':4,5]thieno[2,3-c]pyridazin-3-amine analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4: In one aspect, the invention relates to substituted pyrazolo[3′,4′:4,5]thieno[2,3-c]pyridazine-3-amine analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated... Agent: Vanderbilt University

20140364408 - Hydrazide containing nuclear transport modulators and uses thereof: The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and... Agent: Karyopharm Therapeutics Inc.

20140364411 - Kinase inhibitors: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.... Agent: Chiesi Farmaceutici S.p.a.

20140364412 - Kinase inhibitors: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract... Agent: Chiesi Farmaceutici S.p.a.

20140364413 - Pde 10a inhibitors for the treatment of type ii diabetes: m

20140364414 - Pde 10a inhibitors for the treatment of type ii diabetes:

20140364415 - Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors:

20140364416 - Compositions and methods comprising c16:1n7-palmitoleate: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol... Agent: Tersus Pharmaceuticals, LLC

20140364417 - Method of treating atrial fibrillation: The present disclosure relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a therapeutically effective amount of ivabradine or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of ranolazine. Also provided are methods for modulating ventricular and atrial rate.... Agent:

20140364418 - Compositions comprising an aromatic alcohol and a trpv-1 antagonist, and uses thereof: A topical composition providing reduced irritation that contains aromatic alcohols such as phenoxyethanol and a TRPV-1 antagonist is described. The composition is substantially free of parabens. The composition may be used for example for cleansing the skin.... Agent: Johnson & Johnson Consumer Companies, Inc.

20140364419 - Methods for increasing the stabilization of hypoxia inducible factor-1 alpha: Disclosed herein are methods for controlling the activity of hypoxia-inducible transcription factor 1-alpha (HIF-1α) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are pharmaceutical compositions comprising HIF-1α prolyl hydroxylase inhibitors useful in treating diseases,... Agent:

20140364422 - Aqueous pharmaceutical composition with enhanced stability: The present invention is an aqueous pharmaceutical composition that includes an ionized therapeutic agent, an ionic component and guar gum. The guar gum is present in the composition a concentration sufficient to limit interactions between the ionized therapeutic agent and the ionic component thereby imparting stability to the composition. The... Agent:

20140364421 - Benzothiophene compound: [Means for Solution] As a result of studies on the IK1 channel activator, the present inventors have found that a benzothiophene compound shows effectiveness on visceral pain, inflammatory pain, osteoarthritis pain, neuropathic pain, or fibromyalgia, thereby completing the invention. A compound of the invention has an IK1 channel activation effect,... Agent: Astellas Pharma Inc.

20140364420 - Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone... Agent: Millennium Pharmaceuticals, Inc.

20140364423 - Pyrazinopyrazines and derivatives as kinase inhibitors:

20140364424 - Novel sulfonaminoquinoline hepcidin antagonists: The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.... Agent:

20140364425 - Salts of potassium atp channel openers and uses thereof: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing... Agent:

20140364426 - Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds: o

20140364427 - Estrogen receptor modulators and uses thereof: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon... Agent:

20140364428 - 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives: The present invention relates to novel 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2H-[1,4]oxazin-3-amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds... Agent: Janssen Pharmaceutica Nv

20140364429 - Antiviral compounds highly effective as hcv-ns5a inhibitor: e

20140364430 - Methods for treating schizophrenia: Provided herein are PAK inhibitors. Also provided herein are compositions and methods for treating an individual suffering from schizophrenia... Agent:

20140364431 - Quinoline and cinnoline derivatives and their applications: The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof. And the compounds of general formula I show potent inhibitory activity gainst c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically... Agent:

20140364432 - Substituted prolines / piperidines as orexin receptor antagonists: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated;... Agent:

20140364433 - Substituted prolines / piperidines as orexin receptor antagonists: The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX1 or OX2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated;... Agent:

20140364435 - Amino-substituted imidazopyridazines: The present invention relates to amino-substituted imidazopyndazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and... Agent:

20140364434 - Biomarkers for prediction of response to parp inhibition in breast cancer: Methods and systems for identifying a cancer patient suitable for treatment with a PARP inhibitor. A 6-gene, 7-gene and 8-gene predictor panels of genes that are predictive of patient resistance or sensitivity to PARP inhibitors such as Olaparib.... Agent: The Regents Of The University Of California

20140364436 - Protein kinase inhibitors: t

20140364437 - Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same: The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also... Agent:

20140364438 - Triazolopyridine derivatives as a tyrosine kinase inhibitor: Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.... Agent: Hanmi Pharm. Co., Ltd.

20140364440 - Topical oil composition for the treatment of fungal infections: The present invention is directed to anti-fungal compositions comprising an anti-fungal agent, an oil and excipients or additives. The compositions of the present invention are devoid of C-11 or greater fatty acids/esters.... Agent:

20140364439 - Markers associated with chronic lymphocytic leukemia prognosis and progression: The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (CLL). Examples of these markers include drivers of CLL progression. The invention contemplates, inter alia, detecting the clonal, including subclonal, profile of CLL in a subject and the presence (or absence) of subclonal... Agent: Dana-farber Cancer Institute, Inc.

20140364441 - Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.... Agent:

20140364443 - 1,4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof: Disclosed are 1,4-dihydro-naphthyridine derivatives and pharmaceutical composition and uses thereof. The 1,4-dihydro-naphthyridine derivatives are a compound capable of inhibiting acetylcholinesterase activity and preventing extracellular calcium from flowing into a cell via a calcium channel, i.e., having a dual-activity, which are of potential importance as a pharmaceutical and can be used... Agent: Jiangsu Simovay Pharmaceutical Co., Ltd.

20140364444 - Fused heterocyclic compound and use thereof for pest control: wherein A1 represents —NR8—, and the like; A2 represents a nitrogen atom, and the like; A3 represents a nitrogen atom, and the like; R1 represents a C1-C6 chain hydrocarbon group optionally having one or more atoms or groups selected from Group X, and the like; R2, R3, R4, and R5... Agent:

20140364442 - Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds: e

20140364445 - Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent: The present invention relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist and an anticholinergic agent. Particularly, the present invention provides a pharmaceutical composition comprising a TRPA1 antagonist having IC50 for inhibiting human TRPA1 receptor activity of less than 1 micromolar and an anticholinergic agent;... Agent:

20140364446 - 1',4'-thio nucleosides for the treatment of hcv: e

20140364447 - Dual selective pi3 delta and gamma kinase inhibitors: The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.... Agent:

20140364448 - Quarternized buprenorphine analogs: The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R1, R1a, R2, R8, R3a, R3b, G, X, Z, Y, and A® are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions... Agent: Purdue Pharma L.p.

20140364449 - Method and system for identifying compounds that bind and/or activate a target opioid receptor in a ph-dependent manner: The invention relates to a method for identifying compounds that bind and preferably activate a target opioid receptor in a pH-dependent manner.... Agent: Mathpharm Gmbh

20140364450 - Aminopyridines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.... Agent:

20140364451 - Tropinol esters and related compounds to promote normal processing of app: In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment... Agent: Buck Institute For Research On Aging

20140364454 - Metal-chelating compounds having at least one polyamino chain: The invention relates to metal-chelating compounds comprising one or more 8-hydroxyquinoline units substituted in position 2 with a nitrogenous group comprising a polyamino chain, wherein the polyamino chain is N-substituted on said nitrogenous group, to the composition containing same, and to the uses thereof in the therapeutic field and in... Agent:

20140364452 - Methods to determine susceptibility to treatment with leukotriene modifiers: The present invention provides a method of determining the susceptibility of a subject to treatment with a leukotriene modifier by determining the subject's cysteinyl leukotriene (CysLT) level and the subject's level of eosinophilic airway inflammation and identifying a subject with a high ratio of CysLT levels to eosinophilic airway inflammation... Agent:

20140364453 - Salubrinal-driven attenuation of malignant phenotypes of 4t1 breast cancer cells: A method is disclosed for the in vivo treatment of a breast cancer tumor utilizing a therapeutically effective amount of an agent that inactivates the Rac1 GTPase and results in a reduction in cancer cell invasion, reduced cancer cell motility, and reduced volume and weight of the tumor. Agents that... Agent: Indiana University Research And Technology Corporation

20140364455 - Processes of making and crystalline forms of a mdm2 inhibitor: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.... Agent:

20140364456 - Heterocyclylpyri(mi)dinylpyrazole: Heterocyclylpyri(mi)dinylpyrazole of the formula (I), in which R1 to R5, X1, U, Q, W, a, b and n have the meanings given in the description, and agrochemically active salts, to their use and to methods and compositions for controlling phytopathogenic harmful fungi in and/or on plants or in and/or on... Agent: Bayer Intellectual Property Gmbh

20140364457 - Compositions for reducing ab 42 production and their use in treating alzheimer's disease (ad): Novel small molecule compounds for reduction of Aβ 42 production and for treatment of Alzheimer's disease and other neurodegenerative disorders, methods of making them and pharmaceutical compositions containing them are described.... Agent:

20140364458 - Use of an anthranilic diamide derivatives with heteroaromatic and heterocyclic substituents in combination with a biologicalcontrol agent: in which R1, R2, R3, R4, R5, R6, A, Q and n can have the definitions stated in the description, and at least one biological control agent selected from bacteria, fungi or yeasts, protozoas, viruses, entomopathogenic nematodes, and botanical extracts, or products produced by microorganisms including proteins or secondary metabolites,... Agent:

20140364459 - Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on rosiglitazone therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent:

20140364461 - Method of treating dermatological disorders: A method of treating a dermatological disorder in a subject includes the step of administering a therapeutically effective amount of at least one PPARγ agonist or derivative thereof to the subject.... Agent:

20140364462 - Pyridine derivatives: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these... Agent:

20140364460 - Use of fatostatin for treating cancer having a p53 mutation: Fatostatin, a recently described inhibitor of SREBP activation, significantly reduces the level of mutant p53 binding to the HMG-CoA reductase gene promoter. Further, fatostatin treatment had a dramatic effect on normalizing the abnormal 3D morphology of 3 strains of breast cancer cells: MDA-468 cells, MDA-231 cells, and SKBR3 cells. The... Agent: The Trustees Of Columbia University In The City Of New York

20140364463 - Nicotinic attenuation of cns inflammation and autoimmunity: The present invention relates to methods of treating and/or ameliorating the severity of inflammation and autoimmunity in the central nervous system (CNS). In one embodiment, the present invention provides a method of treating multiple sclerosis by administering a therapeutically effective dosage of nicotine, or a pharmaceutical equivalent, analog, derivative, or... Agent: Dignity Health

20140364464 - Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof: The present invention relates to the field of pharmaceutical chemistry. Disclosed herein is a crystalline form of azilsartan medoxomil potassium, which is substantially pure. The crystalline form is crystalline form A, form B, form C, form D, form E, form F, form G, form H, form I, form J, form... Agent: Ruyuan Hec Pharm Co., Ltd.

20140364465 - Thiazolidinedione derivatives, preparation thereof and use thereof in cancer treatment: The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula (I) and exhibit, at a concentration of 100 μM, a hepatocyte viability preferably greater than 60%,... Agent: Centre National De La Recherch Scientifique - Cnrs

20140364466 - Isothiazoline compounds for combating invertebrate pests: which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes, and to a method for producing them. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition... Agent: Basf Se

20140364467 - Chemical inducers of neurogenesis: The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in... Agent: The Board Of Regents Of The University Of Texas System

20140364468 - Method for treating obesity: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition... Agent:

20140364469 - Fungicide active substance combinations: e

20140364470 - New forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor: The invention relates to a phosphate salt or a nitrate salt of 4-(R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl-3-fluoro-benzonitrile, especially in crystalline form, and specific forms of these salts, as well as related invention embodiments. The salts and salt forms allow for the prophylactic and/or therapeutic treatment of aldosterone synthase and/or aromatase mediated diseases or disorders.... Agent: Novartis Ag

20140364471 - Pharmaceutical compositions comprising poh derivatives: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention... Agent:

20140364472 - Pharmaceutical compositions comprising poh derivatives: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention... Agent:

20140364473 - Oral suspension comprising telmisartan: A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %.... Agent: Boehringer Ingelheim Vetmedica Gmbh

20140364474 - Imidazole derivatives useful for controlling microbial growth: Disclosure is provided for 1,4,5-substituted amino imidazole compounds useful to control microbial growth, compositions including these compounds, devices including these compounds, and methods of using the same.... Agent:

20140364475 - Compositions for the treatment and prevention of eyelid swelling: The invention features topical formulations comprising an osmotically active agent and/or a vasoconsgtrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.... Agent: Aciex Therapeutics, Inc.

20140364476 - Cathepsin c inhibitors: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.... Agent:

20140364477 - Indolyl or indolinyl hydroxamate compounds: s

20140364478 - Plant disease control composition:

20140364479 - Process for the preparation of glycopyrronium chloride: The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications.... Agent: Chiesi Farmaceutici S.p.a.

20140364490 - 1-oxo/acylation-14-acylated oridonin derivative, preparation method therefor and application thereof: The present invention relates to the fields of natural medicine and medicinal chemistry, and more particularly to a 1-oxo/acylated-14-acylated oridonin derivative of a general formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the compounds, a pharmaceutical composition comprising the compounds, and application thereof in preparation of... Agent: Hangzhou Bensheng Pharmaceutical Co., Ltd.

20140364491 - Iron supplement: An orally deliverable dosage system comprises (a) iron in a form of one or more physiologically acceptable iron grades, compounds and/or complexes; and (b) an agent to mitigate one or more gastrointestinal adverse effects of unabsorbed iron, said agent comprising one or both of a zinc component and a chelator... Agent: Amip, LLC

20140364492 - Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same: The present invention relates to a diterpene compound derived from Aleurites fordii, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the... Agent: Korea Research Institute Of Bioscience And Biotechnology

20140364493 - Method of inhibiting remnant lipoprotein production: The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory... Agent: Japan Tobacco Inc.

20140364494 - Processes for making cyclic lipid implants for intraocular use: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.... Agent: Allergan, Inc.

20140364495 - Highly penetrating compositions and methods for treating disordered tissues: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence... Agent:

20140364496 - Highly penetrating compositions and methods for treating disordered tissues: Compositions and methods for treating disordered tissues, such as caused by pathogens and/or by toxins. The treatment compositions include an anti-infective active agent, a liquid carrier, and benzocaine in an amount so that the treatment composition penetrates more quickly into disordered tissue compared to the treatment composition in the absence... Agent:

20140364497 - Pharmaceutical compositions of fenofibrate: The invention relates to pharmaceutical compositions comprising unmicronized fenofibrate in admixture with a wetting agent and one or more pharmaceutically acceptable excipients, wherein the admixture is not comicronized before processing. The invention also relates to processes for the preparation of such compositions.... Agent: Wockhardt Research Centre

20140364498 - Anaplerotic therapy of huntington disease and other polyglutamine diseases: The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.... Agent:

20140364499 - Coriolus versicolor extracts, methods of isolating biologically-active compounds, and uses thereof: The subject invention provides efficient and convenient methods of isolating 9-oxo-10E, 12E-octadecadienoic acid methyl ester (9-KODE methyl ester) from C. versicolor. In addition, the subject invention provides therapeutic uses of Coriolus versicolor extracts, biologically-active chemical substituents isolated from C. versicolor, as well as 9-KODE methyl ester and related compounds. In... Agent:

20140364500 - Ursolic acid salts for treating diabetes and obesity: wherein R is H or OH and X+ is protonated metformin, protonated arginine, protonated lysine and protonated meglumine. The invention also relates to intermediates used in the preparation of such compounds, processes for the preparation of such compounds and intermediates, pharmaceutical compositions comprising such compounds and the methods of treatment... Agent:

20140364501 - Compositions of abscisic acid for animal health: The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of using the same for improving the health and survival of animal offspring.... Agent:

20140364502 - Lipoic acid derivatives: Lipoic acid derivatives and pharmaceutical formulations containing lipoic acid derivatives are useful in the treatment and prevention of disease characterized by disease cells that are sensitive to lipoic acid derivatives.... Agent:

20140364503 - Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container: A ready-to-use injectable, co-solvents (ternary mixture) pharmaceutical composition for the treatment of cardiac conditions and diagnosis applications, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (Esmolol hydrochloride), a buffering agent, ethanol and propylene glycol which capable of been stored in modified flexible plastic container, heat-sterilized without deformation and/or integrity of the closure system been compromised,... Agent: Hq Specialty Pharma Corporation

20140364504 - Broad spectrum pharmacological composition for treatmentof various infections and diseases and methodsof use: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate... Agent:

20140364505 - Lytic agents for use in treating intravascular clots: Agents and methods are provided for breaking down and/or assisting in the removal of clots, in embodiments chronic clots, from the vasculature. In embodiments, the agents and methods may be used in the vasculature, in particular the peripheral venous vasculature, in order to prevent clot formation and/or lyse clots in... Agent:

20140364506 - Deuterium enriched rasagiline: The subject invention provides deuterated rasagiline, its salts and uses.... Agent: Teva Pharmaceutical Industries, Ltd.

20140364507 - Methods for identifying inhibitors of mannan-binding lectin-associated serine protease (masp) proteins and uses thereof: This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.... Agent: University Of Leicester

20140364508 - Small molecule xanthine oxidase inhibitors and methods of use: Small molecule xanthine oxidase inhibitors are provided, as well as methods for their use in treating gout or hyperuricemia.... Agent:

20140364509 - Alcohol based sanitizer with improved dermal compatibility and feel: Applicants have identified a critical skin benefit package that can be used in liquid alcohol sanitizing compositions that provides lower amounts of skin conditioners in combination with a specific ratio of different emollients that provide improved skin health with chronic repeated use. The package also provides improved skin feel with... Agent:

20140364510 - Controlled release aural pressure modulator compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris... Agent:

20140364511 - Surfactant responsive micro-gels: A stable, aqueous composition containing a crosslinked, nonionic, amphiphilic polymer capable of forming a yield stress fluid in the presence of a surfactant is disclosed. The yield stress fluid is capable of suspending insoluble materials in the form of particulates and/or droplets requiring suspension or stabilization.... Agent: Lubrizol Advanced Materials, Inc.

20140364512 - Compositions comprising a combination of at least one colorant and at least one polysaccharide: Dispersible colorants that include a combination of a colorant and a polysaccharide are provided, wherein the weight ratio of total colorant to total polysaccharide is in the range of 5000:1 to 1:5000. In one aspect, the colorant is a synthetic or natural colorant. In one aspect, polysaccharide is interpreted very... Agent: Epc (beijing) Natural Products Co., Ltd.

20140364513 - Highly robust fast-disintegrating tablet and process for manufacturing the same: Disclosed are an oral formulation which disintegrates quickly in the oral cavity; a fast-disintegrating tablet having fast disintegrability and high hardness, and a process for manufacturing the same. In addition, slightly wetted granules for manufacturing said fast-disintegrating tablet and a process for manufacturing the same are disclosed.... Agent:

20140364514 - Co-attrited stabilizer composition having superior gel strength: The present invention is directed to a co-attrited stabilizer composition comprising: a) microcrystalline cellulose in an amount of from 20%-90% by weight of the composition; b) a hydrocolloid in an amount of from 5%-50% by weight of the composition, wherein the hydrocolloid is selected from at least one member of... Agent: Fmc Corporation

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141218: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.83406 seconds

PATENT INFO